TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30710467

Group type: EXPERIMENTAL
Intervention: High risk indication from WGS test for Alzheimer's disease
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: High risk indication from WGS test for macular degeneration
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: High risk indication from WGS test for colon cancer
Number of subjects: 909
Study: 29913020

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 28 days
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 512
Study: 26891839

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (monthly cash transfer conditional on school attendance)
Number of subjects: 2533

Group type: COMPARATOR
Intervention: Control group (no cash transfer)
Number of subjects: 2533
Study: 25406046

Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22984272

Group type: EXPERIMENTAL
Intervention: MTX plus IFX
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 40
Study: 20515216

Group type: EXPERIMENTAL
Intervention: Combination treatment (psychotherapy and pharmacotherapy)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Cognitive behavioral analysis system of psychotherapy (monotherapy)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Nefazodone (monotherapy)
Number of subjects: 504
Study: 16862549

Group type: EXPERIMENTAL
Intervention: Low-energy laser intervention applied for 5 days following the start of chemotherapy.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no laser intervention).
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-energy laser intervention and control group comparison.
Number of subjects: 60
Study: 16142782

Group type: EXPERIMENTAL
Intervention: Microwave electromagnetic field (450 MHz, 0.16 mW/cm2) with 7 Hz modulation frequency
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 10
Study: 12132977

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg, twice daily for 7 weeks)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo (twice daily for 7 weeks)
Number of subjects: 600
Study: 11329104

Group type: EXPERIMENTAL
Intervention: Digoxin pretreatment (group A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Procainamide pretreatment (group B)
Number of subjects: 56
Study: 7572947

Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole cell (BS‐WC) or killed whole cell‐only (WC) oral cholera vaccines
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1981748

Group type: EXPERIMENTAL
Intervention: mifentidine 20 mg at night
Number of subjects: 60

Group type: COMPARATOR
Intervention: ranitidine 300 mg at night
Number of subjects: 60
Study: 6452464

Group type: EXPERIMENTAL
Intervention: 4% topical erythromycin liquid with 1.2% zinc acetate applied twice daily
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 4% topical erythromycin gel with 1.2% zinc octoate applied twice daily
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 250 mg of oral tetracycline twice daily
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 31159739

Group type: EXPERIMENTAL
Intervention: Conventional ultrafiltration targeting a haematocrit (HCT) level of 28%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-ultrafiltration (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional ultrafiltration
Number of subjects: 60
Study: 28416344

Group type: EXPERIMENTAL
Intervention: Sunbed intervention (twice weekly exposure for 12 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no sunbed exposure)
Number of subjects: 31
Study: 25087839

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 25 mg BIW during Cycle 2 after relapse
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg BIW for < 12 weeks (or ETN 25 mg BIW for an extra 12 weeks until PGA < 2 was achieved) during Cycle 1
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Patient Satisfaction Survey during Cycle 1
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Patient Satisfaction Survey during Cycle 2
Number of subjects: 131
Study: 23591085

Group type: EXPERIMENTAL
Intervention: Whey protein drink (HP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (HC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 10
Study: 21892119

Group type: EXPERIMENTAL
Intervention: Topical treatment with PDGF applied weekly to the TM for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo applied weekly to the TM for 6 weeks
Number of subjects: 20
Study: 19487613

Group type: EXPERIMENTAL
Intervention: Intervention group (5 clinics)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (5 clinics)
Number of subjects: 10
Study: 17225163

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 12
Study: 15076238

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) at a dose of 4 mg daily (DD)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) at a dose of 4 mg on alternate days (AD)
Number of subjects: 245

Group type: COMPARATOR
Intervention: All groups (DD, AD, PL)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: DD-AD and AD-AD
Number of subjects: 245
Study: 11474953

Group type: EXPERIMENTAL
Intervention: Deep breathing with a blow bottle-device
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Inspiratory resistance-positive expiratory pressure mask (IR-PEP)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Deep breathing with no mechanical device
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 98
Study: 9100214

Group type: EXPERIMENTAL
Intervention: High intensity exercise (HIE: 500 calories 75% VO2 max)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low intensity exercise (LIE: 500 calories 50% VO2 max)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High intensity exercise (HIE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low intensity exercise (LIE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition (C) of quiet sitting for 1 hour
Number of subjects: 8
Study: 7962341

Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GHRH (2 micrograms/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg) plus GHRH (2 micrograms/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg) plus Arginine (0.5 g/kg)
Number of subjects: 29
Study: 2887418

Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐mononitrate (Imdur) 60mg once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 29160000

Group type: EXPERIMENTAL
Intervention: Autologous keratin and fibroblast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 30
Study: 27073242

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Angiographic obliteration
Number of subjects: 292

Group type: COMPARATOR
Intervention: Before SRS
Number of subjects: 292
Study: 24076415

Group type: EXPERIMENTAL
Intervention: Daily coffee consumption
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Coffee consumption at age 18
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ever daily smoking
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Age at diagnosis for ever daily smokers
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hormonal contraception use in females
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Number of children before PSC diagnosis
Number of subjects: 240
Study: 23327226

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP35)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20% hydrogen peroxide (HP20)
Number of subjects: 60
Study: 20722756

Group type: EXPERIMENTAL
Intervention: Instruments 30, 0.02 taper
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Instruments 35, 0.02 taper
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Instruments 40, 0.02 taper
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Instruments 45, 0.02 taper
Number of subjects: 44
Study: 18568314

Group type: COMPARATOR
Intervention: Cypher stent (279 patients)
Number of subjects: 34677

Group type: COMPARATOR
Intervention: Taxus stent (318 patients)
Number of subjects: 34677

Group type: COMPARATOR
Intervention: Endeavor stent (239 patients)
Number of subjects: 34677

Group type: COMPARATOR
Intervention: Cypher stent
Number of subjects: 34677

Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 34677

Group type: COMPARATOR
Intervention: Three studies with primary surrogate endpoint (DIABETES, SCORPIUS, ISAR-DIABETES)
Number of subjects: 34677

Group type: COMPARATOR
Intervention: Meta-analysis of Cypher patients (627 patients)
Number of subjects: 34677

Group type: COMPARATOR
Intervention: Meta-analysis of Taxus patients (814 patients)
Number of subjects: 34677
Study: 16608136

Group type: EXPERIMENTAL
Intervention: Group-based strength training (n=34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (n=34)
Number of subjects: 68
Study: 12702114

Group type: EXPERIMENTAL
Intervention: BDX + collagen membrane
Number of subjects: 28

Group type: COMPARATOR
Intervention: Access flap surgery
Number of subjects: 28
Study: 11731754

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg i.v.)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg i.v.)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg i.v.) followed by Ketorolac (30 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups (K, T, KT)
Number of subjects: 51
Study: 9040549

Group type: EXPERIMENTAL
Intervention: Formula 8 (iron approximately 143 mumol/L or 8 mg/L)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Similac with Iron (iron approximately 215 mumol/L or 12 mg/L)
Number of subjects: 52
Study: 7730891

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2889255

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg once daily at bedtime for 4 weeks
Number of subjects: 234

Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily at bedtime for 4 weeks
Number of subjects: 234
Study: 29560939

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg orally per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Previous NSAID therapy (control)
Number of subjects: 40
Study: 28161554

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/d
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 26327301

Group type: EXPERIMENTAL
Intervention: Siltuximab (11 mg/kg administered intravenously every 3 weeks, or every 6 weeks at investigator's discretion)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Siltuximab
Number of subjects: 19
Study: 23204550

Group type: EXPERIMENTAL
Intervention: Neridronate 100 mg i.v. infusion given four times over 10 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Neridronate (open label after 50 days)
Number of subjects: 82
Study: 21753156

Group type: EXPERIMENTAL
Intervention: LY2334737 monotherapy (40 mg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: LY2334737 in combination with erlotinib (100 mg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: LY2334737 monotherapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: LY2334737
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: LY2334737 drug formulations
Number of subjects: 65
Study: 19192477

Group type: EXPERIMENTAL
Intervention: Intramuscular second-generation antipsychotics (SGAs)
Number of subjects: 3425

Group type: COMPARATOR
Intervention: Intramuscular haloperidol alone
Number of subjects: 3425

Group type: COMPARATOR
Intervention: Intramuscular haloperidol plus promethazine
Number of subjects: 3425
Study: 16607104

Group type: EXPERIMENTAL
Intervention: Isoflavones
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Equol producers (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-equol producers (n = 15)
Number of subjects: 30
Study: 14664280

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 11688

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 11688
Study: 10856868

Group type: EXPERIMENTAL
Intervention: Bilateral extracorporeal circulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Routine extracorporeal circulation
Number of subjects: 18
Study: 9367289

Group type: EXPERIMENTAL
Intervention: Altitude hypoxia (4350m above sea level) for four days
Number of subjects: 10
Study: 31794507

Group type: EXPERIMENTAL
Intervention: Modified unilateral open‐door laminoplasty with posterior muscle‐ligament complex preservation
Number of subjects: 63
Study: 28815614

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25738952

Group type: EXPERIMENTAL
Intervention: Focus on Youth (FOY) media
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Promoting Health Among Teens (PHAT) media
Number of subjects: 1613

Group type: COMPARATOR
Intervention: General health curriculum (PHAT non-media)
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: Culturally-tailored media intervention
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Focus on Youth (FOY) non-media
Number of subjects: 1613
Study: 23340117

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS to contralateral dPMC
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham-rTMS protocol
Number of subjects: 12
Study: 19721433

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 738
Study: 18664984

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (CIP) for 6-8 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Topical framycetin-gramicidin-dexamethasone (FGD) for 6-8 weeks
Number of subjects: 97
Study: 15976212

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g and Propacetamol 2 g
Number of subjects: 152
Study: 14692430

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10668523

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 0
Study: 8765824

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) solution
Number of subjects: 43

Group type: COMPARATOR
Intervention: Topical steroids (beclomethasone dipropionate (BD) ointment)
Number of subjects: 43
Study: 1913269

Group type: EXPERIMENTAL
Intervention: Fragments of Pool 2 (fSRW)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Conventional ragweed preparation (Pool 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Histamine (placebo)
Number of subjects: 3
Study: 6807934

Group type: COMPARATOR
Intervention: Detergent wash
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-phenate solution (1:16 dilution, 10 minute immersion)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 119
Study: 30880807

Group type: EXPERIMENTAL
Intervention: Structured DVD education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard one‐on‐one education
Number of subjects: 0
Study: 28976989

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/day for 12 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 27019001

Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg and Everolimus 10 mg, both once daily for 4 weeks (1 cycle)
Number of subjects: 24
Study: 24285427

Group type: EXPERIMENTAL
Intervention: 5 mg vitamin K1 orally thrice weekly
Number of subjects: 348

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 348
Study: 22323353

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Exercise-Diet
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control (Healthy Lifestyle)
Number of subjects: 309
Study: 18677491

Group type: EXPERIMENTAL
Intervention: Aiming arm group (AA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Free hand (FH) group
Number of subjects: 20
Study: 17552400

Group type: EXPERIMENTAL
Intervention: High compression plus amelogenin
Number of subjects: 83

Group type: COMPARATOR
Intervention: High compression therapy alone
Number of subjects: 83
Study: 15526982

Group type: EXPERIMENTAL
Intervention: triptorelin (GnRH agonist)
Number of subjects: 46

Group type: COMPARATOR
Intervention: ganirelix (GnRH antagonist)
Number of subjects: 46
Study: 11200962

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 28
Study: 9591441

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream or ointment applied to lesional skin twice daily for 7-19 days
Number of subjects: 40
Study: 7814359

Group type: EXPERIMENTAL
Intervention: Continuation treatment (3-6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance treatment (6-24 months)
Number of subjects: 0
Study: 3336995

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study: 31449956

Group type: EXPERIMENTAL
Intervention: Directional atherectomy combined with DCB angioplasty (n = 45)
Number of subjects: 94

Group type: COMPARATOR
Intervention: DCB angioplasty alone (n = 49)
Number of subjects: 94
Study: 31436146

Group type: EXPERIMENTAL
Intervention: Modified gown with increased skin coverage at the hands and wrists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education on donning and doffing technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard gown
Number of subjects: 0
Study: 28498853

Group type: EXPERIMENTAL
Intervention: DAR-901 (1 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 16
Study: 26071347

Group type: EXPERIMENTAL
Intervention: Three doses of HPV-16/18 vaccine
Number of subjects: 24055

Group type: EXPERIMENTAL
Intervention: Two doses of HPV-16/18 vaccine
Number of subjects: 24055

Group type: EXPERIMENTAL
Intervention: One dose of HPV-16/18 vaccine
Number of subjects: 24055

Group type: EXPERIMENTAL
Intervention: Two doses of HPV-16/18 vaccine (second dose at 1 month)
Number of subjects: 24055

Group type: EXPERIMENTAL
Intervention: Two doses of HPV-16/18 vaccine (second dose at 6 months)
Number of subjects: 24055
Study: 23877287

Group type: EXPERIMENTAL
Intervention: Educational Method 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational Method 2
Number of subjects: 0
Study: 22162639

Group type: EXPERIMENTAL
Intervention: Oxy-ER (5 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Oxy-CRF (5 mg)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Oxy-ER (40 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Oxy-CRF (40 mg)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Oxy-ER (40 mg) after high-fat breakfast
Number of subjects: 103

Group type: COMPARATOR
Intervention: Oxy-CRF (40 mg) after high-fat breakfast
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Oxy-ER
Number of subjects: 103

Group type: COMPARATOR
Intervention: Oxy-CRF
Number of subjects: 103
Study: 19485429

Group type: COMPARATOR
Intervention: peginterferon-alpha-2b plus ribavirin for 48 weeks (PEG + R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: peginterferon-alpha-2b plus ribavirin according to German guidelines (GUIDE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: interferon-alpha-2b plus ribavirin for 48 weeks (IFN + R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GUIDE
Number of subjects: 0

Group type: COMPARATOR
Intervention: PEG + R
Number of subjects: 0
Study: 16826006

Group type: EXPERIMENTAL
Intervention: Macro discectomy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Microdiscectomy
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 119
Study: 12567387

Group type: EXPERIMENTAL
Intervention: 100 microg HFA‐BDP
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 200 microg HFA‐BDP
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 200 microg HFA‐BDP after ingestion of charcoal
Number of subjects: 14

Group type: COMPARATOR
Intervention: 400 microg CFC‐BDP
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HFA treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gastrointestinal absorption of BDP
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 17‐BMP metabolism
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Steady-state volume of distribution of 17‐BMP
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Terminal half-life after inhalations
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: i.v. administration of BDP
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HFA Autohaler vs CFC-pMDI
Number of subjects: 14
Study: 10833680

Group type: EXPERIMENTAL
Intervention: Progressive Relaxation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 67

Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 67

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 67